Biotech Values

[oc631]

Perhaps if just an effect on weight loss they will move forward in just a general obese population?

It's hard to justify a study like this from a company that's short on cash. Their strategy appears to highlight efficacy without clearly demonstrating safety which should be the goal in Phase 1. Obesity is a tough indication considering the high bar set on safety.